Skip to main content
Clinical Trials/NCT03083366
NCT03083366
Terminated
N/A

The Effectiveness of Early Sacral Nerve Stimulation in Improving Bladder- Related Complications and Quality of Life After Acute Traumatic Spinal Cord Injury

University of Utah2 sites in 1 country5 target enrollmentAugust 7, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Spinal Cord Injury, Acute
Sponsor
University of Utah
Enrollment
5
Locations
2
Primary Endpoint
Maximum Cystometric Capacity
Status
Terminated
Last Updated
10 months ago

Overview

Brief Summary

The purpose of this study is to see what effects sacral neuromodulation has on bladder function and quality of life in patients with acute spinal cord injury. Within 12-weeks of injury, participants will either receive an implanted nerve stimulator (like a pace-maker for the bladder) or standard care for neurogenic bladder. Patients will be assigned to one of these groups at random and followed for one year. The hypothesis is that early stimulation of the nerves will help prevent the development of neurogenic bladder.

Registry
clinicaltrials.gov
Start Date
August 7, 2019
End Date
April 20, 2023
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jeremy Myers

Associate Professor of Surgery

University of Utah

Eligibility Criteria

Inclusion Criteria

  • Age \> 18 years
  • Ability to implant device less than 12 weeks post-spinal cord injury (SCI)
  • Presence of acute SCI at or above T12
  • American Spinal Injury Association (ASIA) Scale A or B
  • Expectation to perform clean intermittent catheterization (CIC) personally or have caretaker perform CIC

Exclusion Criteria

  • Inability to perform CIC
  • Pre-existing SCI
  • Pre-existing progressive neurological disorder
  • Autonomic dysreflexia
  • Prior sacral back surgery
  • Posterior pelvic fracture with distortion of the sacroiliac joint
  • Prior urethral sphincter or bladder dysfunction
  • Chronic urinary tract infections prior to SCI
  • Pregnancy at the time of enrollment
  • Presence of coagulation disorder or need for anticoagulation that they cannot be stopped temporarily for procedure

Outcomes

Primary Outcomes

Maximum Cystometric Capacity

Time Frame: 12 months

Maximum bladder capacity as measured by urodynamic study at 12 months

Quality of Life Differences Measured by Mean SCI-QoL

Time Frame: 12 months

Participant-reported quality of life as assessed by the Spinal Cord Injury - Quality of Life (SCI-QOL) bladder question banks at 12 months. Scores range from 64-320 with a lower score indicating greater satisfaction with quality of life.

Number of Urinary Tract Infections Requiring Antibiotics

Time Frame: from enrollment through the end of follow-up at 12 months

Secondary Outcomes

  • Maximum Cystometric Capacity at 3 Months(3 months)
  • Bladder Compliance(3, 12 months)
  • Presence of Detrusor Overactivity(3, 12 months)
  • Pressure at First Detrusor Contraction(3, 12 months)
  • Volume at First Detrusor Contraction(3, 12 months)
  • Daily Number of Catheterizations(3, 6, 9, 12 months)
  • Average Catheterization Volume(3, 6, 9, 12 months)
  • Urinary Incontinence Episodes Per Day(3, 6, 9, 12 months)
  • 24 Hour Pad Weight Test(3, 6, 9, 12 months)
  • Development of Hydronephrosis(12 months)
  • Need for Anticholinergic Medication(from enrollment through the end of follow-up at 12 months)
  • Need for Onabotulinum Toxin A Injection(from enrollment through the end of follow-up at 12 months)
  • Need for Device Revision(from implant through the end of follow-up at 12 months)
  • Device Explanation(from implant through the end of follow-up at 12 months)
  • Hospitalizations(from enrollment through the end of follow-up at 12 months)
  • Urologic Related Surgeries(from enrollment through the end of follow-up at 12 months)
  • Death(from enrollment through the end of follow-up at 12 months)

Study Sites (2)

Loading locations...

Similar Trials